Global Antiviral Drugs Market 2017-2021

  • ID: 4143934
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
until May 31st 2018
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AbbVie
  • Bristol-Myers Squibb
  • F Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • MORE
About Antiviral Drugs

Antiviral drugs are agents used to cure a viral infection by inhibiting the growth of viral pathogens. There are two types of antiviral agents which includes narrow-spectrum antiviral agents and broad-spectrum antiviral agents.

The analysts forecast the global antiviral drugs market to grow at a CAGR of 9.48% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global antiviral drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of antiviral drugs.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Antiviral Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Gilead Sciences
- GlaxoSmithKline

Other prominent vendors
- AbbVie
- Johnson & Johnson
- Merck
- Novartis

Market drivers
- Stockpiling by public healthcare agencies
- For a full, detailed list, view the full report

Market challenges
- Need for proper storage conditions of antiviral drugs
- For a full, detailed list, view the full report

Market trends
- Technological advancements
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the Key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Bristol-Myers Squibb
  • F Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • MORE
PART 01: Executive summary

PART 02: Research Methodology

PART 03: Introduction
  • Key market highlights
  • Key vendor offerings
PART 04: Disease Overview
  • Viral disease
PART 05: Market landscape
  • Market overview
  • Five forces analysis
PART 06: Pipeline analysis

PART 07: Market segmentation by therapies
  • Global hepatitis therapeutics market
  • Global HIV/AIDS therapeutics market
  • Global herpes therapeutics market
  • Global influenza therapeutics market
PART 08: Market segmentation by MOA
  • Reverse transcriptase inhibitors
  • Protease inhibitors
  • Entry/Fusion inhibitors
  • Immune system modulators
PART 09: Geographical segmentation
  • Antiviral drugs market in Americas
  • Antiviral drugs market in EMEA
  • Antiviral drugs market in APAC
PART 10: Decision framework

PART 11: Drivers and challenges
  • Market drivers
  • Impact of drivers on key customer segments
  • Market challenges
  • Forcefield analysis of impact of drivers and challenges
PART 12: Market trends
  • Technological advancements
  • Combination therapy
  • Mergers and acquisitions
  • Growing partnerships
PART 13: Competitive Landscape
  • Competitive scenario
PART 14: Key vendor analysis
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Few major products offered by the key vendors
Exhibit 02: HIV treatment regimen approved by FDA
Exhibit 03: Hepatitis treatment regimen approved by FDA
Exhibit 04: Herpes treatment regimen approved by FDA
Exhibit 05: Global antiviral drugs market snapshot
Exhibit 06: Key marketed products
Exhibit 07: Global antiviral drugs market 2016-2021 ($ billions)
Exhibit 08: Opportunity analysis of global antiviral drugs market
Exhibit 09: Snapshot of pipeline molecules (2016)
Exhibit 10: Pipeline analysis
Exhibit 11: Global antiviral drugs market segmentation by therapies
Exhibit 12: Acute hepatitis cases in US 2000-2014
Exhibit 13: Global hepatitis therapeutics market 2016-2021 ($ billions)
Exhibit 14: Global HIV/AIDS therapeutics market 2016-2021 ($ billions)
Exhibit 15: Number of women patients with HSV 2 in US 2000-2014
Exhibit 16: Global herpes therapeutic market 2016-2021 ($ billions)
Exhibit 17: Global influenza therapeutics market 2016-2021 ($ billions)
Exhibit 18: Global antiviral drugs market segmentation by MOA
Exhibit 19: Market share of different segments based on MOA 2016
Exhibit 20: Global antiviral drugs market segmentation by geography 2016 and 2021
Exhibit 21: Global antiviral drugs market revenue by geography 2016-2021 ($ billions)
Exhibit 22: Market scenario in Americas
Exhibit 23: Antiviral drugs market in Americas 2016-2021 ($ billions)
Exhibit 24: Market scenario in EMEA
Exhibit 25: Antiviral drugs market in EMEA 2016-2021 ($ billions)
Exhibit 26: Market scenario in APAC
Exhibit 27: Antiviral drugs market in APAC 2016-2021 ($ billions)
Exhibit 28: Seasonal influenza vaccine: Total doses distributed in millions
Exhibit 29: Impact of drivers
Exhibit 30: Impact of challenges
Exhibit 31: Competitive structure analysis of global antiviral drugs market 2016
Exhibit 32: Competitive analysis of global antiviral drugs market
Exhibit 33: Bristol-Myers Squibb: Geographical segmentation in terms of revenue in 2015
Exhibit 34: Bristol-Myers Squibb: Strength assessment
Exhibit 35: Bristol-Myers Squibb: Strategy assessment
Exhibit 36: Bristol-Myers Squibb: Opportunity assessment
Exhibit 37: F. Hoffman-La Roche: Strength assessment
Exhibit 38: F. Hoffman-La Roche: Strategy assessment
Exhibit 39: F. Hoffman-La Roche: Opportunity assessment
Exhibit 40: Gilead Sciences: Strength assessment
Exhibit 41: Gilead Sciences: Strategy assessment
Exhibit 42: Gilead Sciences: Opportunity assessment
Exhibit 43: GlaxoSmithKline: Strength assessment
Exhibit 44: GlaxoSmithKline: Strategy assessment
Exhibit 45: GlaxoSmithKline: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie
  • Bristol-Myers Squibb
  • F Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • MORE
New Report Released: – Global Antiviral Drugs Market 2017-2021

The author of the report recognizes the following companies as the key players in the global antiviral drugs market: Bristol-Myers Squibb, F. Hoffmann-La Roche, Gilead Sciences, and GlaxoSmithKline.

Other Prominent Vendors in the market are: AbbVie, Johnson & Johnson, Merck, and Novartis.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is technological advancements. The new hybridoma technique is a novel approach toward the development of monoclonal antibodies, which are selective in nature. This technique will not only have a positive impact against viral diseases but also decrease the cost of the overall treatment. It can be expected that antiviral agents, which were above $100 and could be used to control an epidemic effectively, can now be produced at 1% of its original cost.”

According to the report, one of the major drivers for this market is stockpiling by public healthcare agencies. The CDC estimates that government organizations such as the WHO are also taking initiatives to secure public health during future outbreak of viral diseases by increasing the antiviral drugs stock. The CDC manages the Strategic National Stockpile, which includes storage of bulk quantities of antiviral medications for public health emergencies.

Further, the report states that one of the major factors hindering the growth of this market is need for proper storage conditions of antiviral drugs. Antiviral drugs should be stored at a moderate temperature that is neither too hot, nor too cold. These medications are temperature sensitive and their therapeutic efficacy is lost if proper storage temperature is not maintained.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Bristol-Myers Squibb
  • F Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline
  • AbbVie
  • Johnson & Johnson
  • Merck
  • Novartis
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll